Track record · closed signal

Pfizer Inc. (PFE) — closed signal from July 2, 2025

Partial Published before the outcome was known, scored automatically when the window closed on September 30, 2025.

Predicted vs. what happened

PFE price · publication thesis → realized outcomesplit-adjusted

$22.40 – $23.10Entry zone — fair-value band

$24.19Published — price the day we called it

$27.11Target — the price the thesis aimed for

$25.66Peak — highest point inside the window, not a realized return

$25.04Window close — end-of-window price, context only

What happened

Partial

Reached 38% of the predicted growth at its peak, without hitting the target.

Peak price

$25.66

peak on August 22, 2025 — not a realized return

Peak gain

+6.1%

peak, from the publication price

Window close

$25.04

end-of-window price, context only

Days to target

—

Window

July 2, 2025 – September 30, 2025

The thesis — published July 2, 2025

Predicted growth

+16%

over the measurement window

Target price

$27.11

the price the thesis aimed for

Entry zone

$22.40 – $23.10

the fair-value band we waited for

Price at publication

$24.19

published July 2, 2025

Confidence

68%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Pfizer just spent $6.7 billion to enter medical cannabis, which has excited investors and drawn in a surge of buyers. The share price has climbed so quickly that it looks winded, yet the stock still offers a 5.5 percent yearly dividend. Waiting for the price to cool to about $24 gives a calmer entry before aiming for the high $28 area in the next few months. This pause also lets the market absorb hopes for new weight-loss drugs and cost savings.

Primary drivers

$6.7 billion cannabis move adds new products and grabs Wall Street attention
Surge in trading shows many more buyers, but a breather would be healthy
5.5% dividend pays you while you wait for the next upward swing
Sharp rally plus mixed mood means bumps ahead, so buying dips makes sense

How it played out

PFE: target was not reached

Lyra published PFE at $24.19 on 2025-07-02 with an expected 16% move and a $27.11 target. The thesis pointed to a $6.7 billion cannabis move, a surge in trading, a 5.5% dividend, and hopes around weight-loss drugs and cost savings. It also said the rally looked winded and that a pause would help.

Inside the window, PFE rose to a $25.66 peak on 2025-08-22, a 6.1% gain. It never reached $27.11. By 2025-09-30, it ended at $25.04. The direction was right, but the published target was missed.

What happened during the window

On 2025-09-30, Pfizer and the Trump administration announced a drug-pricing agreement tied to a new direct-purchase platform. Pfizer also said it would make a $70 billion U.S. investment in research, development, and manufacturing.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All PFE signals